A randomized study evaluating the continuation of bevacizumab  beyond progression in metastatic colo...
Download
1 / 22

Disclosure: Gianluca Masi - PowerPoint PPT Presentation


  • 123 Views
  • Uploaded on

A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Gruppo Oncologico Nord Ovest (GONO).

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Disclosure: Gianluca Masi' - inari


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

A randomized study evaluating the continuation of bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the GruppoOncologico Nord Ovest (GONO).

G. Masi1, F. Loupakis1, L. Salvatore1, L. Fornaro1, C. Cremolini1, M. Schirripa1, E. Fea2,C. Granetto2, L. Antonuzzo3, E. Giommoni3, G. Allegrini4, S. Cupini5, C. Boni6, M. Banzi6, S. Chiara7, C. Sonaglio7, C. Valsuani8, A. Bonetti9, L. Boni10, A. Falcone1,11

1) Pisa, Italy; 2) Cuneo, Italy; 3) Firenze, Italy; 4) Pontedera, Italy; 5) Livorno, Italy 6) Reggio Emilia, Italy; 7) Genova, Italy; 8) Lido di Camaiore, Italy; 9) Legnago, Italy; 10) Istituto Toscano Tumori, Firenze, Italy; 11) Università di Pisa, Italy.


Disclosure: bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the GianlucaMasi

  • Honoraria: Roche, Merck-Serono, Amgen

  • ResearchFunding: Roche


Background bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

  • BV plus fluoropyrimidine-based CT is a standard first-line treatment in mCRC pts.

  • Retrospective data from BRITE and ARIES studies suggested that the continuation of BV with second line CT beyond progression was associated with improved survival 1,2.

  • A recent phase III study (AIO/AMG ML18147) demonstrated an improved survival with BV beyond progression 3.

  • Grothey et al. JCO 2008;26:5326-34

  • Cohn et al. JCO 2010;28(15s):Abstr 3596

  • Arnold et al. JCO 2012;30 (suppl; abstr CRA3503)


Study bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Design

R

A

N

D

O

M

A. Second-line CT§

  • I-line CT * + BV

  • Stratification

  • Center

  • PS 0/1-2

  • CT-free interval

  • (> vs ≤ 3 mos)

  • II-line CT

B. Second-line CT§+ BV

*

  • FOLFIRI

  • FOLFOX

  • FOLFOXIRI

  • Fluoropyrimidine mono-tx

  • FOLFIRI

  • mFOLFOX-6

§

  • Study conducted in 19 Italian centers

  • Supported by AIFA


Treatment schedules bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

  • FOLFIRI

  • IRINOTECAN 180 mg/sqmi.v. over 1 hr on day 1 concomitantly with

  • l-LV 200 mg/sqmi.v. over 2 hrs on days 1 followed by

  • 5-FU 400 mg/sqmi.v. bolus on days 1 followed by

  • 5-FU 2400 mg/sqmi.v. by c.i. over 46 hrs on days 1

  • cycles repeated every 2 weeks

  • mFOLFOX-6

  • OXALIPLATIN 85 mg/sqmi.v. over 1 hr on day 1 concomitantly with

  • l-LV 200 mg/sqmi.v. over 2 hrs on days 1 followed by

  • 5-FU 400 mg/sqmi.v. bolus on days 1 followed by

  • 5-FU 2400 mg/sqmi.v. by c.i. over 46 hrs on days 1

  • cycles repeated every 2 weeks

  • In pts randomized to the BV containing arm the regimens were associated with:

  • BEVACIZUMAB5 mg/kgi.v. on day 1 (immediately before irinotecan or oxaliplatin) repeated every 2 weeks


Objectives bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

  • Primary

  • Progression Free Survival

  • Secondary

  • Response Rate

  • Overall Survival

  • Safety

  • Potential markers predictive of BV activity


Statistical Design / bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Accrual

  • Original Hypothesis

    • To detect a HR for PFS of 0.70 in favor of CT+BV

    • Power=80%; alpha, two-sided=0.05

    • Required 249 events and a total of 262 pts

  • Accrual started on April 8th 2008 and was stopped prematurely on May 11th 2012

    • Press release of TML study results with OS improvement

    • Slow accrual rhythm due to bevacizumab supply limitation

  • Randomized 185 pts (184 pts for ITT) (1 pt randomized twice)


Main Eligibility Criteria bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

  • Pts with histologicallyconfirmedcolorectaladenoca

  • Age >18 yrs and <75 yrs

  • ECOG PS 0-2

  • Unresectable and measurable metastatic disease according to RECIST criteria

  • Progressive disease after or during first-line CT with fluoropyrimidine, FOLFIRI, FOLFOX + BV or >3 mos after the last dose of FOLFOXIRI + BV


Patients’ characteristics (1) bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

* By central analysis


Patients’ characteristics (2) bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the


Second-line CT on the bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the basis of first-line CT


Primary Objective - PFS bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

CT (85 events) median PFS = 4.97 mos

CT+ B (87 events) median PFS = 6.77 mos

HR=0.65 (95%CI 0.48-0.89)

p=0.0062

Median follow up 18.0 mos


Subgroup Analysis of PFS bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

*

* Test of interaction


Response Rate bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

* p not statistically significant (0,71)

** p not statistically significant (0,21)


Overall bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Safety

* CNS ischemia


Maximum bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Toxicities per patient(CT related)


Maximum bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the Toxicities per patient(Beva-related)


Subsequent anti-cancer therapies bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the


Overall Survival bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

  • OS data are still immature

  • After a median follow up of 18 months we observed 52 events in arm A (CT) and 46 events in arm B (CT+BV)


Summary bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

  • Bevacizumab beyond progression significantly improved PFS

    • CT vs CT+BV: mPFS 4.97 vs 6.77 months

    • HR=0.65 (95% CI 0.48-0.89), p=0.0062

  • Data from subgroup analyses for PFS consistent with overall population

  • No significant differences in RR and DCR

  • OS data still immature

  • Safety profile consistent with previously reported data


  • Conclusions bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

    • Second randomized trial investigating the impact of BV continuation beyond first progression

    • Our results are in line with those of TML

    • The prosecution of BV in combination with second-line CT represents a new treatment option


    Acknowledgements bevacizumab beyond progression in metastatic colorectal cancer patients who received bevacizumab as part of first-line treatment: results of the BEBYP trial by the

    • Patients and their caregivers

    • AIFA

    • Dr. Luca BoniCentro CoordinamentoSperimentazioniCliniche, IstitutoToscanoTumori

    • Investigators

    • Pisa (A. Falcone, G. Masi, F. Loupakis, L. Salvatore, C. Cremolini, M. Schirripa, L. Fornaro)

    • Cuneo (M. Merlano, C. Granetto, E. Fea)

    • Livorno (F. Cappuzzo, S. Cupini, C. Barbara)

    • Firenze (F. Di Costanzo, L. Antonuzzo, E. Giommoni)

    • Reggio Emilia (C. Boni, M. Banzi, R. Gnoni)

    • Genova IST (P. Pronzato, S. Chiara, C. Sonaglio)

    • Versilia (D. Amoroso, C. Valsuani)

    • Pontedera (G. Allegrini, L. Marcucci, S. Lucchesi)

    • Legnago (A. Bonetti, F. Greco)

    • Piombino (F. Dargenio, V. Safina)

    • Biella (M. Clerico)

    • Lecce (V. Lorusso, A. Gambino)

    • Novara (O. Alabiso)

    • Siena (S. Crispino, S. Biancanelli, A. Martignetti)

    • Fabriano (RR Silva, E. Galizia)

    • Pesaro (V. Catalano)

    • Caltanissetta (S. Vitello)

    • Empoli (G. Fiorentini)

    • Parma (A. Ardizzoni)


    ad